Are Medical Stocks Lagging Corcept Therapeutics (CORT) This Year?Zacks Investment Research • 07/23/26
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness Wire • 07/22/26
Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should KnowThe Motley Fool • 07/21/26
A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and ReboundThe Motley Fool • 07/21/26
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion OutlookThe Motley Fool • 07/12/26
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For InvestorsSeeking Alpha • 07/10/26
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law FirmPRNewsWire • 06/25/26
Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's SyndromeBusiness Wire • 06/17/26
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane ExposureBusiness Wire • 05/29/26
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock UpZacks Investment Research • 05/28/26
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's SyndromeBusiness Wire • 05/27/26
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to TradeZacks Investment Research • 05/19/26
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?Zacks Investment Research • 05/15/26
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook RaisedZacks Investment Research • 05/01/26
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/01/26
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral SclerosisBusiness Wire • 04/30/26
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate UpdateBusiness Wire • 04/30/26
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference CallBusiness Wire • 04/23/26